[{"orgOrder":0,"company":"Imagine Pharma","sponsor":"IP Investors LLC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"IMG-1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Imagine Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imagine Pharma \/ IP Investors LLC","highestDevelopmentStatusID":"6","companyTruncated":"Imagine Pharma \/ IP Investors LLC"}]

Find Clinical Drug Pipeline Developments & Deals by Imagine Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : The net proceeds will be used to advance the company's priority programs in regenerative medicine, oral delivery, and therapeutics and for the continued development of its novel IMG-1 polypeptide.

                          Product Name : IMG-1

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 31, 2023

                          Lead Product(s) : IMG-1

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : IP Investors LLC

                          Deal Size : $32.5 million

                          Deal Type : Series A Financing

                          blank